ADC Therapeutics SA (ADCT)
| Market Cap | 192.71M -60.7% |
| Revenue (ttm) | 84.87M +12.9% |
| Net Income | -81.25M |
| EPS | -0.53 |
| Shares Out | 140.66M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,169,898 |
| Open | 1.340 |
| Previous Close | 1.350 |
| Day's Range | 1.310 - 1.410 |
| 52-Week Range | 0.780 - 4.980 |
| Beta | 1.80 |
| Analysts | Buy |
| Price Target | 3.33 (+143.29%) |
| Earnings Date | Nov 9, 2026 |
About ADCT
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue... [Read more]
Financial Performance
In 2025, ADC Therapeutics's revenue was $81.36 million, an increase of 14.85% compared to the previous year's $70.84 million. Losses were -$142.62 million, -9.64% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ADCT stock is "Buy." The 12-month stock price target is $3.33, which is an increase of 143.29% from the latest price.
News
ADC Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
LOTIS-7 showed an 89% ORR and 75% CR rate in 2L+ DLBCL, with phase III planning targeted for 2027. ZYNLONTA’s MZL data support planned FDA discussions and a potential accelerated approval pathway.
ADC Therapeutics registers to sell 61M common shares for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 61M common shares. The company is not selling any shares under…
ADC Therapeutics Registration statement: Registration filing
ADC Therapeutics filed a registration statement on November 10, 2026, providing details about a securities offering with the SEC.
ADC Therapeutics Slides: Corporate presentation
ADC Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 10, 2026.
ADC Therapeutics reports Q3 adjusted EPS (6c) vs. (19c) last year
Reports Q3 revenue $21.0M, consensus $19.07M. As of September 30 cash and cash equivalents were $189.2M compared to $261.3M as of December 31, 2025, a change primarily driven by cash…
ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates
Third quarter 2026 net product revenue of $21 million; cash and cash equivalents of $189.2 million as of September 30, 2026 Strategic financial restructuring strengthens balance sheet, extending expec...
ADC Therapeutics Earnings release: Q3 2026
ADC Therapeutics released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
ADC Therapeutics Earnings release: Q3 2026
ADC Therapeutics released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
ADC Therapeutics Quarterly report: Q3 2026
ADC Therapeutics has published its Q3 2026 quarterly earnings report on November 9, 2026.
ADC Therapeutics Transcript: Investor update
LOTIS-7 showed an 88.7% ORR and 75.3% CR rate; MZL ORR was 93%. Restructuring extended expected cash runway into 2029.
ADC Therapeutics Slides: Investor update
ADC Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 4, 2026.
ADC Therapeutics Press release: Investor update
ADC Therapeutics issued a press release on November 4, 2026, disclosing material business information to investors.
ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program
ZYNLONTA data to be featured across 5 oral presentations and multiple posters Phase 1b LOTIS-7 abstract data demonstrates an 88.7% ORR and 75.3% CR with ZYNLONTA plus glofitamab across the 97 efficacy...
ADC Therapeutics to Present at November Investor Conferences
LAUSANNE, Switzerland, Nov. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced part...
ADC Therapeutics Announces New Employee Inducement Grant
LAUSANNE, Switzerland, Nov. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026
LAUSANNE, Switzerland, Nov. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
ADC Therapeutics provides Zynlonta updates in Japan
ADC Therapeutics (ADCT)’ Japanese licensing partner, Tanabe Pharma, filed a marketing authorization application with Japan’s Ministry of Health, Labor and Welfare on October 29 for Zynlonta – loncastu...
ADC Therapeutics Announces ZYNLONTA® Updates in Japan
Licensing partner, Tanabe Pharma, filed for Japanese approval of ZYNLONTA (MT-2111) for relapsed or refractory DLBCL based on encouraging Japanese Phase 1/2 clinical results Tanabe Pharma entered into...
ADC Therapeutics announces comprehensive strategic financial restructuring
ADC Therapeutics (ADCT) announced a comprehensive strategic financial restructuring designed to strengthen its balance sheet, reduce leverage, increase strategic optionality and extend cash runway int...
ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
$86.6 Million Private Placement announced, with participation from new and existing investors, extending expected cash runway into 2029 HealthCare Royalty financing agreement amended, removing change...
These beaten-down stocks could bounce back in January, if history is any guide
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
ADC Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
ZYNLONTA demonstrates strong efficacy and safety in DLBCL and marginal zone lymphoma, with promising results from combination studies and ongoing regulatory engagement. Key upcoming milestones include ASH data releases and a robust cash position supports continued development.
ADC Therapeutics Slides: 12th Annual Cantor Fitzgerald Global Healthcare Conference
ADC Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 11, 2026.
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
LAUSANNE, Switzerland, Sept. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2026 Cantor...
ADC Therapeutics price target lowered to $5 from $10 at Guggenheim
Guggenheim analyst Michael Schmidt lowered the firm’s price target on ADC Therapeutics (ADCT) to $5 from $10 and keeps a Buy rating on the shares. ADC Therapeutics faces increased regulatory…